Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 9/20 | 0.46 |
| ▸ | ABL1 | P00519 | 10/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30698659 | 1.00 | MAP4K1 (0.46) | MAP4K1ABL1GSK3BDYRK1A | |
| SCHEMBL27038862 | 1.00 | MAP4K1 (0.46) | MAP4K1ABL1GSK3BDYRK1A | |
| SCHEMBL30698712 | 0.89 | ABL1 (0.49) | MAP4K1ABL1 | |
| SCHEMBL27038843 | 0.89 | ABL1 (0.49) | MAP4K1ABL1 | |
| SCHEMBL27037599 | 0.83 | ABL1 (0.51) | MAP4K1ABL1 | |
| SCHEMBL30698895 | 0.83 | ABL1 (0.51) | MAP4K1ABL1 | |
| SCHEMBL30698733 | 0.80 | MAP4K1 (0.55) | MAP4K1ABL1GSK3BDYRK1A | |
| SCHEMBL27038323 | 0.80 | MAP4K1 (0.50) | MAP4K1ABL1 | |
| SCHEMBL30699234 | 0.80 | MAP4K1 (0.50) | MAP4K1ABL1 | |
| SCHEMBL27037252 | 0.80 | MAP4K1 (0.55) | MAP4K1ABL1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |